High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2390-2396

  Rijkaart, D C ^a   Heideman, D A M ^a   Coupe, V M H ^a   Brink, A A T P ^a,d   Verheijen, R H M ^b   Skomedal, H ^c   Karlsen, F ^c   Morland, E ^c   Snijders, P J F ^a   Meijer, C J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NorChip AS   (Norway)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CYTOLOGY; DIAGNOSTIC KIT; DIAGNOSTIC VALUE; DYSKARYOSIS; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RNA ANALYSIS; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; AGED; CYTOLOGICAL TECHNIQUES; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; RNA, VIRAL; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

EID: 84862726786     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.06587-11     Document Type: Article

References (48)

1. Anderson MC. 1995. Premalignant and malignant squamous lesions of the cervix, p 292-297. In Fox H, Wells M (ed), Haines and Taylor obstetrical and gynaecological pathology. Churchill Livingstone, New York, NY.
2. Anttila A, et al. 2010. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 340:c1804. doi:10.1136/bmj.c1804.
3. Arbyn M, et al. 2006. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl 3):S78-S89.
4. Benevolo M, et al. 2011. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes Control 22:869-875.
5. Benevolo M, et al. 2011. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J. Clin. Microbiol. 49:2643-2650.
6. Berkhof J, et al. 2006. HPV type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol. Biomarkers Prev. 15:1268-1273.
7. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ. 2004. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J. Clin. Pathol. 57:388-393.
8. Bulkmans NW, et al. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772.
9. Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. 2005. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br. J. Cancer 92:1800-1802.
10. Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. 2011. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol. Oncol. 120:430-438.
11. Carozzi F, et al. 2008. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 9:937-945.
12. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. 2007. Risk assessment to guide the prevention of cervical cancer. Am. J. Obstet. Gynecol. 197:356.
13. Cuschieri KS, Beattie G, Hassan S, Robertson K, Cubie H. 2005. Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium. J. Virol. Methods 124:211-215.
14. Cuschieri KS, Whitley MJ, Cubie HA. 2004. Human papillomavirus type specific DNA and RNA persistence - implications for cervical disease progression and monitoring. J. Med. Virol. 73:65-70.
15. Cuzick J, et al. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101.
16. Cuzick J, et al. 2008. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology - results from the Hammersmith study. Int. J. Cancer 122:2294-2300.
17. Guan P, et al. 2012. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int. J. Cancer doi:10.1002/ijc.27485.
18. Hesselink AT, et al. 2011. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin. Cancer Res. 17:2459-2465.
19. Jacobs MV, et al. 1997. A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol. 35:791-795.
20. Khan MJ, et al. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072-1079.
21. Kitchener HC, et al. 2009. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10:672-682.
22. Kraus I, et al. 2004. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br. J. Cancer 90:1407-1413.
23. Mayrand MH, et al. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357:1579-1588.
24. Molden T, Kraus I, Karlsen F, Skomedal H, Hagmar B. 2006. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gynecol. Oncol. 100:95-100.
25. Molden T, et al. 2005. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol. Biomarkers Prev. 14:367-372.
26. Molden T, et al. 2005. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL pap smear. Int. J. Cancer 114:973-976.
27. Munoz N, et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
28. Naucler P, et al. 2009. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl. Cancer Inst. 101:88-99.
29. Naucler P, et al. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357:1589-1597.
30. Petry KU, et al. 2011. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol. Oncol. 121:505-509.
31. Ratnam S, et al. 2010. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J. Clin. Microbiol. 48:2779-2785.
32. Ratnam S, et al. 2011. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J. Clin. Microbiol. 49:557-564.
33. Rijkaart DC, et al. 2012. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: results over two screening rounds of the POBASCAM randomized controlled trial. Lancet Oncol. 13:78-88.
34. Rijkaart DC, et al. 2012. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int. J. Cancer 130:602-610.
35. Ronco G, et al. 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11:249-257.
36. Ronco G, et al. 2008. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 100:492-501.
37. Snijders PJ, et al. 2006. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int. J. Cancer 119:1102-1107.
38. Sorbye SW, Fismen S, Gutteberg T, Mortensen ES. 2010. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One 5:e12724. doi:10.1371/journal. pone.0012724.
39. Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES. 2010. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J. Virol. Methods 169:219-222.
40. Taha NS, et al. 2006. Universal Collection Medium (UCM) is as suitable as the Standard Transport Medium (STM) for Hybrid Capture II (HC-2) assay. J. Clin. Virol. 36:32-35.
41. van den Brule AJ, et al. 2002. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 40:779-787.
42. van Duin M, et al. 2002. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int. J. Cancer 98:590-595.
43. Varnai AD, et al. 2008. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol. Rep. 19:457-465.
44. Walboomers JM, et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
45. Wentzensen N, et al. 2006. Identification of high-grade cervical dysplasia by the detection of p16(INK4a) in cell lysates obtained from cervical samples. Cancer 107:2307-2313.
46. Wright TC. 2009. Precancerous lesions of the cervix, p 248-257. In Kurman RJ (ed), Blaustein's pathology of the female genital tract, 4th ed. Springer Verlag, New York, NY.
47. Ylitalo N, et al. 2000. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355:2194-2198.
48. zur Hausen H. 2000. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92:690-698.